Document:

Exhibits
10.2

 

HARRELL
CORPORATE CONSULTING AGREEMENT

 

This
Consulting Agreement (the “Agreement”) is made as of May 5, 2016, by and between OptimizeRx
Corporation, a Nevada corporation, with offices at 400 Water, Rochester, Michigan 48307 (“OptimizeRx”) and
David Harrell (“Consultant”) (each a “Party” and collectively the “Parties”),

 

BACKGROUND

 

A.OptimizeRx
is a technology solutions company targeting the healthcare industry.

 

B.Consultant
has experience in all aspects of OptimizeRx, its business, technology, customer base and market as Founder and previous CEO.

 

C.The
Parties are seeking to utilize the Consultant to support OptimizeRx management in developing effective strategies, partnerships
and innovation that further accelerates growth.

 

In
consideration of the mutual promises contained herein, the parties hereby agree as follows:

 

AGREEMENT

 

1.            Services

 

During
the Consulting Period (defined below), the Consultant will assist OptimizeRx management in developing strategy, partnerships,
alliances, and business opportunities (“Services”). The Consultant shall provide up to (at OptimizeRx’s election)
100 hours monthly to this effort and receive compensation under the provisions of this agreement.

 

2.            ENGAGEMENT

 

2.1
Subject to the terms and conditions of this Agreement, OptimizeRx hereby retains the Consultant as an independent consultant for
a sixteen month period unless sooner terminated as provided herein (the "Consulting Period") beginning as of
June 1, 2016 and ending September 30, 2017. Consultant’s primary contact at OptimizeRx shall be Will Febbo, Chief Executive
Officer, or such other person or persons who may be appointed by OptimizeRx (the "OptimizeRx Representative").
The Services will be further defined on an ongoing basis by the OptimizeRx Representative. Without limitation, Consultant shall
undertake such tasks, provide such reports and attend such meetings as the OptimizeRx Representative may reasonably request. Consultant
shall be responsible for determining the method, details and means of performing the Services and shall consult with the OptimizeRx
Representative on a regular basis about the nature, quality and direction of the Services. Consultant will decide where and when
the Services are best performed. Consultant may not subcontract or delegate any of the Services without the prior consent of the
OptimizeRx Representative.

 

     

     

    

 

2.2
The parties expressly acknowledge and agree that OptimizeRx is engaging the Consultant as an independent contractor. Consultant
shall not have the right, power, or authority to bind OptimizeRx or to make any contract or other agreement or assume or create
any obligation or liability, express or implied, on OptimizeRx’s behalf. Consultant will not be eligible to participate
in any vacation, group medical or life insurance, disability, profit sharing or retirement benefits or any other fringe benefits
or benefit plans offered by OptimizeRx to its employees.

 

2.3
In performing hereunder, Consultant shall comply with OptimizeRx policies and procedures and the reasonable instructions of the
OptimizeRx Representative as well as all applicable laws, including the Foreign Corrupt Practices Act, the Health Insurance Portability
and Accountability Act of 1996, and other federal and state laws regarding healthcare marketing and protection of personal information.

 

3.            COMPENSATION

 

3.1
During the Consulting Period, OptimizeRx shall pay Consultant a consulting fee of $15,000.00 per month payable under OptimizeRx’s
normal payroll timeframes (“Consulting Fee”). OptimizeRx shall reimburse the Consultant on a monthly basis for pre-approved,
reasonable and necessary expenses incurred by the Consultant on behalf of OptimizeRx in the performance of the Consultant’s
duties during the Consulting Period (including but not limited to reasonable travel expenses) which are otherwise acceptable in
accordance with OptimizeRx's standard expense reimbursement practices for its independent contractors and which have been approved
in advance by the OptimizeRx Representative. Consultant shall submit expenses for reimbursement in writing with supporting receipts
and documentation in accordance with the Internal Revenue Code and regulations or as otherwise required under OptimizeRx’s
expense reimbursement procedures in effect from time to time.

 

3.2
In the event OptimizeRx achieves or exceeds the annual total revenues and net income (loss) in 2016 that are set forth in its
2016 annual budget approved by the Board of Directors in March, 2016 OptimizeRx shall pay the Consultant a bonus of $27,000. In
the event OptimizeRx achieves or exceeds the total annual revenues and net income (loss) in 2017 that are set forth in the 2017
annual budget approved by the Board of Directors, OptimizeRx shall pay the Consultant a bonus of $27,000. If Consultant is not
privy to the 2017 annual budget because he is no longer a member of the Board of Directors, OptimizeRx will provide that portion
of the 2017 annual budget pertaining to total annual revenues and net income (loss) goals in 2017, provided Consultant signs a
non-disclosure agreement. No bonuses shall be due for a year in which the total annual revenues and net income (loss) are not
achieved.

 

3.3.
OptimizeRx shall pay Consultant a lump sum of $9,664 as an allowance for Consultant to purchase individual healthcare coverage.
The Parties agree that this allowance will be sufficient to allow the Consultant to purchase his own individual healthcare coverage
for a period of seven months. Consultant will be responsible for acquiring the coverage and to pay for any charges incurred to
upgrade that coverage. This allowance is a one-time payment and will not reoccur on any renewal of the Consulting Period.

 

    	 	2	 

     

    

 

4.            PRICING 

 

Under
this Agreement the product prices for services offered by OptimizeRx shall be determined by OptimizeRx, although insight by the
Consultant will be considered. OptimizeRx shall approve all proposals prior to being submitted to prospects and clients.

 

5.
           TERM AND TERMINATION

 

5.1
If both parties so agree in writing, the Consulting Period may be renewed on a month-to-month basis, beginning on October 1, 2017.
Otherwise it shall terminate on September 30, 2017.

 

5.2
Either party may terminate this Agreement for cause, effective immediately upon written notice to the other, in the event that
the other a) breaches any of the terms, representations, warranties or conditions of this Agreement and fails to cure same within
fifteen (15) days of notice thereof or b) engages in any illegal activity, reckless behavior or fraud. If this agreement is terminated
by OptimizeRx for cause, no bonus under Section 3.2 shall be due for the year in which such termination occurs or any subsequent
year. If this agreement is terminated by Consultant for cause, the remainder of total amount of 18 month of service will be due
to Consulting.

 

5.3
Provisions of this agreement that by their nature should reasonably survive its termination shall so survive including without
limitation Sections 7 and 9.

 

6.            Confidentiality, Invention Assignment and Non-Compete

 

As
a condition of this Agreement, the Consultant will execute and deliver to OptimizeRx the Consultant Confidentiality, Invention
Assignment and Non-Compete Agreement, attached as attachment A the terms of which are incorporated herein by reference.
Any breach thereof shall constitute a material breach hereof. Any breach thereof shall constitute a material breach hereof. Any
breach by Employee of the Separation Agreement And Release dated May 5, 2016 between Employee and Company including the non-disparagement
provisions thereof, shall constitute a material breach hereof.

 

7.            Independent Contractor; Payment of Taxes 

 

The
Consultant is not a partner, agent employee or joint venture of the OptimizeRx. The Consultant is and shall be deemed an independent
contractor, and shall be solely responsible for and pay when due all estimated tax, withholding, social security, disability,
unemployment, self-employment and other taxes imposed on the Consultant by the U.S. government or any other domestic or non-domestic,
federal, state, or local tax jurisdiction. OptimizeRx will not be responsible for withholding or paying any income, payroll, Social
Security or other federal, state or local taxes, making any insurance contributions, including unemployment or disability, or
obtaining worker's compensation insurance on behalf of Consultant. Consultant shall be responsible for, and shall indemnify OptimizeRx
against, all such taxes or contributions, including penalties and interest. Any persons employed or engaged by Consultant in connection
with the performance of the Services will be Consultant’s employees or contractors and Consultant shall be fully responsible
for them and indemnify OptimizeRx against any claims made by or on behalf of any such employee or contractors.

 

    	 	3	 

     

    

 

8.            Governing
Law and Venue

 

This
Agreement shall be governed by and interpreted in accordance with the laws of the State of Michigan, without regard to its conflict
of law principles or the United Nations Convention on the International Sale of Goods. All disputes arising out of this Agreement
shall be exclusively resolved by a court of competent jurisdiction in the State of Michigan. Each party expressly consents to
the jurisdiction of the courts of the State of Michigan and the Federal District Court for the District of Detroit, and waives
any objections or right as to the forum non-conveniens, lack of personal jurisdiction or similar grounds.

 

9.            INDEMNIFICATION

 

Consultant
shall indemnify, defend and hold harmless OptimizeRx and its employees, agents and affiliated entities against any claim, damage
or liability, including reasonable defense costs that may result from any third party claim caused by a breach of this Agreement
by, or the negligence or willful misconduct of, Consultant; provided that the indemnity hereunder shall not be applicable to the
extent such damages are proximately caused by the breach, negligence or willful misconduct of the Company.

 

OptimizeRx
shall indemnify, defend and hold harmless Consultant, agents and affiliated entities against any claim, damage or liability, including
reasonable defense costs that may result from any third party claim caused by a breach of this Agreement by, or the negligence
or willful misconduct of OptimizeRx; provided that the indemnity hereunder shall not be applicable to the extent such damages
are proximately caused by the breach, negligence or willful misconduct of the Consultant.

 

10.          Miscellaneous

 

10.1   Notices.
Any notice or other communication to be given hereunder will be in writing and given by express receipted courier or overnight
mail, postpaid registered or certified mail return receipt requested, or electronic mail (with a copy concurrently mailed as set
forth above). The date of receipt shall be deemed the date on which such notice is given. Notice hereunder will be directed to
a Party at the address for such Party set forth in the first paragraph of this Agreement or such other address of which a Party
provides notice thereof.

 

10.2    Assignment.
Neither Party will transfer or assign any rights or delegate any obligations hereunder, in whole or in part, whether voluntarily
or by operation of law, without the prior written consent of the other Party. Any purported transfer, assignment or delegation
by either Party without the appropriate prior written approval will be null and void and of no force or effect.

 

    	 	4	 

     

    

 

10.3   Headings.
Sections, titles or captions in no way define, limit, extend or describe the scope of this Agreement nor the intent of any of
its provisions.

 

10.4   Severability.
Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction will, as to such jurisdiction, be ineffective
to the extent of such prohibition or unenforceability without invalidating the remaining portions hereof or affecting the validity
or enforceability of such provision in any other jurisdiction.

 

10.5   Entire
Agreement. This Agreement contains the entire agreement of the parties with respect to the subject matter hereof, and supersedes
all prior and/or contemporaneous agreements or understandings, written or oral, between the parties with respect to the subject
matter hereof.

 

10.6   Amendment.
This Agreement may not be amended or modified by the parties in any manner, except by an instrument in writing signed on behalf
of each of the Parties to which such amendment or modification applies by a duly authorized officer or Consultant.

 

10.7   Waiver.
Any of the provisions of this Agreement may be waived by the Party entitled to the benefit thereof. Neither Party will be deemed,
by any act or omission, to have waived any of its rights or remedies hereunder unless such waiver is in writing and signed by
the waiving Party, and then only to the extent specifically set forth in such writing. A waiver with reference to one event will
not be construed as continuing or as a bar to or waiver of any right or remedy as to a subsequent event.

 

10.8   Force
Majeure. Except for the obligation to pay amounts when due hereunder, neither party shall be responsible for failure to perform
the terms of this Agreement when performance is prevented by force majeure provided that: (1) notice and reasonably full
details of the force majeure are given to the other party; and (2) that the effects of such force majeure are mitigated so
far as possible with commercially reasonable efforts. The term “force majeure” shall mean acts of God, earthquakes,
fire, flood, war, civil disturbances, governmentally imposed rules, regulations or moratoriums, or any similar causes not within
the reasonable control of either party which through the exercise of due diligence, a party is unable to foresee or mitigate.
In no event shall the term force majeure include normal or reasonably foreseeable or reasonably avoidable operational delays.

 

10.9   Counterparts.
This Agreement may be executed in any number of counterparts with the same effect as if both parties hereto had signed the same
document. All counterparts will be construed together and will constitute one agreement.

 

    	 	5	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their respective duly authorized officers or
Consultant on the day first written above.

 

	OPTIMIZERX CORPORATION	 
	 	 	 
	By:	/s/ Douglas
    Baker	 
	Name:	Douglas Baker	 
	Title:	Chief Financial Officer	 
	 	 	 
	David
    Harrell	 
		 	 
	/s/
    David Harrell	 

 

    	 	6	 

     

    

 

Attachment
A

 

Confidentiality,
Invention Assignment and Non-Compete AgreementExhibits
10.3

 

CONSULTANT
CONFIDENTIALITY, INVENTION 

ASSIGNMENT
AND NON-COMPETE AGREEMENT 

 

THIS
CONSULTANT CONFIDENTIALITY, INVENTION ASSIGNMENT AND NON-COMPETE AGREEMENT (“Agreement”) is made as of the date set
forth on the signature page below between OptimizeRx Corp. (“OptimizeRx”), and the person whose name is set forth
on the signature page below as Consultant (“Consultant”).

 

In
consideration of the Consulting Agreement entered into between the Consultant and OptimizeRx, with the intention that this Agreement
shall apply to the entire period of the Consulting Agreement with OptimizeRx (including the period prior to the date of this Agreement),
Consultant hereby agrees as follows:

 

1.
CONFIDENTIAL INFORMATION DEFINED. “Confidential Information” means trade secrets, proprietary information and materials,
and confidential knowledge and information which includes, but is not limited to, matters of a technical nature (such as discoveries,
ideas, concepts, designs, drawings, specifications, techniques, models, diagrams, test data, scientific methods and know-how,
and matters of a business nature (such as the identity of customers and prospective customers, the nature of work being done for
or discussed with customers or prospective customers, suppliers, marketing techniques and materials, marketing and development
plans, pricing or pricing policies, financial information, plans for further development, and any other information of a similar
nature not available to the public).

 

“Confidential
Information” shall not include information that: (a) was in Consultant’s possession or in the public domain before
receipt from the Company, as evidenced by the then existing publication or other public dissemination of such information in written
or other documentary form; (b) becomes available to the public through no fault of Consultant; (c) is received in good faith by
Consultant from a third party who is not subject to an obligation of confidentiality to the Company or any other party; or (d)
is required by a judicial or administrative authority or court having competent jurisdiction to be disclosed by Consultant, provided
that Consultant shall promptly notify the Company and allow the Company a reasonable time to oppose or limit such order.

 

2.
NON-DISCLOSURE OF CONFIDENTIAL INFORMATION OF OPTIMIZERX. Consultant acknowledges that, during the period of Consultant’s
consulting with OptimizeRx, Consultant has had or will have access to Confidential Information of OptimizeRx. Therefore, Consultant
agrees that both during and after the period of Consultant’s consulting with OptimizeRx, Consultant shall not, without the
prior written approval of OptimizeRx, directly or indirectly (a) reveal, report, publish, disclose or transfer any Confidential
Information of OptimizeRx to any person or entity, or (b) use any Confidential Information of OptimizeRx for any purpose or for
the benefit of any person or entity, except as may be necessary in the performance of Consultant’s work for OptimizeRx.

 

3.
NON-DISCLOSURE OF CONFIDENTIAL INFORMATION OF OTHERS. Consultant acknowledges that, during the period of Consultant’s consulting
with OptimizeRx, Consultant may have had or will have access to Confidential Information of third parties who have given OptimizeRx
the right to use such Confidential Information, subject to a non-disclosure agreement between OptimizeRx and such third party.
Therefore, Consultant agrees that both during and after the period of Consultant’s consulting with OptimizeRx, Consultant
shall not, without the prior written approval of OptimizeRx, directly or indirectly (a) reveal, report, publish, disclose or transfer
any Confidential Information of such third parties to any person or entity, or (b) use any Confidential Information of such third
parties for any purpose or for the benefit of any person or entity, except as may be necessary in the performance of Consultant’s
work for OptimizeRx.

 

     

     

    

 

4.
PROPERTY OF OPTIMIZERX. Consultant acknowledges and agrees that all Confidential Information of OptimizeRx and all reports, drawings,
blueprints, materials, data, code, notes and other documents and records, whether printed, typed, handwritten, videotaped, transmitted
or transcribed on data files or on any other type of media, and whether or not labeled or identified as confidential or proprietary,
made or compiled by Consultant, or made available to Consultant, during the period of Consultant consulting with OptimizeRx (including
the period prior to the date of this Agreement) concerning OptimizeRx’s Confidential Information are and shall remain OptimizeRx’s
property and shall be delivered to OptimizeRx within five (5) business days after the termination of such consulting with OptimizeRx
or at any earlier time on request of OptimizeRx. Consultant shall not retain copies of such Confidential Information, documents
and records.

 

5.
PROPRIETARY NOTICES. Consultant shall not, and shall not permit any other person to, remove any proprietary or other legends or
restrictive notices contained in or included in any Confidential Information.

 

6.
INVENTIONS.

 

(a)
Consultant shall promptly, from time to time, fully inform and disclose to OptimizeRx in writing all inventions, copyrightable
material, designs, improvements and discoveries of any kind which Consultant now has made, conceived or developed (including prior
to the date of this Agreement), or which Consultant may later make, conceive or develop, during the period of Consultant’s
consulting with OptimizeRx, which pertain to OptimizeRx’s business (“Inventions”). For greater certainty, OptimizeRx’s
business deals with communications of copay savings, vouchers and clinical messaging for pharma, biotech and diagnostic companies.
OptimizeRx specifically owns SampleMD, a software application which delivers an automated system that replaces traditional physical
drug samples by enabling doctors or other healthcare providers to automatically print and electronically distribute sample vouchers
or co-pay discount coupons within their ePrescribing/ EHR (electronic health record) system or from their computer desktops. OptimizeRx
plans to offer and is in testing for the following: its Voucher DVM for distributing coupons for Veterinary clinics or offices;
its system called “Invite a Rep” to allow physicians to contact their pharmaceutical rep, set up appointments; and
its Consumer App that allows consumers to search for prescriptions savings on their mobile phone. Additionally, OptimizeRx offers
Drug File Integration support services and sales training to their sponsoring clients. This covenant applies to all such Inventions,
whether or not they are eligible for patent, copyright, trademark, trade secret or other legal protection; and whether or not
they are conceived and/or developed by Consultant alone or with others; and whether or not they are conceived and/or developed
during regular working hours; and whether or not they are conceived and/or developed at OptimizeRx’s facility or not.

 

(b)
Inventions shall not include any inventions made, conceived or developed by Consultant prior to Consultant’s consulting
with OptimizeRx, a complete list of which is set forth on Schedule A attached. In addition, Inventions shall not include
any inventions made, conceived or developed by Consultant that do not pertain to OptimizeRx’s business. 

 

(c)
All Inventions , as determined under the provisions listed in Section 6a and 6b, shall be the sole and exclusive property of OptimizeRx,
and shall be deemed part of the Confidential Information of OptimizeRx for purposes of this Agreement, whether or not fixed in
a tangible medium of expression. Consultant hereby assigns all Consultant’s rights in all Inventions and in all related
patents, copyrights and trademarks, trade secrets and other proprietary rights therein to OptimizeRx. Without limiting the foregoing,
Consultant agrees that any copyrightable material shall be deemed to be “works made for hire” and that OptimizeRx
shall be deemed the author of such works under the United States Copyright Act, provided that in the event and to the extent such
works are determined not to constitute “works made for hire”, Consultant hereby irrevocably assigns and transfers
to OptimizeRx all right, title and interest in such works.

 

    	 	2	 

     

    

 

(d)
Consultant shall assist and cooperate with OptimizeRx, both during and after the period of Consultant’s consulting with
OptimizeRx, at OptimizeRx’s sole expense, to allow OptimizeRx to obtain, maintain and enforce patent, copyright, trademark,
trade secret and other legal protection for the Inventions. Consultant shall sign such documents, and do such things necessary,
to obtain such protection and to vest OptimizeRx with full and exclusive title in all Inventions against infringement by others. 

 

(e)
Consultant shall not be entitled to any additional compensation for any and all Inventions made during the period of Consultant’s
consulting with OptimizeRx.

 

7.
COVENANT NOT TO COMPETE. Consultant and OptimizeRx agree that the services rendered by the Consultant are unique and irreplaceable,
and that competitive use and knowledge of any Confidential Information would substantially and irreparably injure OptimizeRx’s
business, prospects and good will. Consultant and OptimizeRx also agree that OptimizeRx’s business is global in nature due
to the type of products and/or services being provided. Therefore, Consultant agrees that during the period of Consultant’s
consulting with OptimizeRx and for a period of twelve (12) months, Consultant shall not, directly or indirectly, through any other
person, firm, corporation or other entity (whether as an officer, director, Consultant, partner, consultant, holder of equity
or debt investment, lender or in any other manner or capacity):

 

(a)
develop, sell, market, offer to sell products and/or services where OptimizeRx markets their business that have the same or similar
technological approach or technology platform, offered or sold by OptimizeRx on the date of the termination of Consultant’s
consulting with OptimizeRx for any reason;

 

(b)
solicit, induce, encourage or attempt to induce or encourage any employee or consultant of OptimizeRx to terminate his or her
employment or consulting relationship with OptimizeRx, or to breach any other obligation to OptimizeRx;

 

(c)
solicit, interfere with, disrupt, alter or attempt to disrupt or alter the relationship, contractual or otherwise, between OptimizeRx
and any consultant, contractor, customer, potential customer, or supplier of OptimizeRx; or

 

(d)
engage in or participate in any business in the same industry as OptimizeRx which is conducted under any name that shall be the
same as or similar to the name of OptimizeRx or any trade name used by OptimizeRx.

 

Consultant
acknowledges that the foregoing geographic, activity and time limitations contained in this Section 7 are reasonable and properly
required for the adequate protection of OptimizeRx’s business. In the event that any such geographic, activity or time limitation
is deemed to be unreasonable by a court, Consultant shall submit to the reduction of either said activity or time limitation to
such activity or period as the court shall deem reasonable. In the event that Consultant is in violation of the aforementioned
restrictive covenants, then the time limitation thereof shall be extended for a period of time equal to the pendency of such proceedings,
including appeals.

 

8.
REPRESENTATIONS. Consultant represents that Consultant has the right to enter into this Agreement, and that Consultant’s
performance of all the terms of this Agreement and his duties as an Consultant of OptimizeRx will not breach any confidential
information agreement, non-competition agreement or other agreement with any former employer of his services, either as an Consultant,
consultant, contractor or independent contractor, or with any other party. Consultant represents that Consultant will not disclose
to OptimizeRx any trade secrets or confidential or proprietary information of any third party that are not generally available
to the public.

 

    	 	3	 

     

    

 

9.
DISCLOSURE OF THIS AGREEMENT. Consultant hereby authorizes OptimizeRx to notify others, including but not limited to customers
of OptimizeRx and any of Consultant’s future employers, of the terms of this Agreement and Consultant’s responsibilities
under this Agreement.

 

10.
SPECIFIC PERFORMANCE. Consultant acknowledges that money damages alone may not adequately compensate OptimizeRx in the event of
a breach or threatened breach by Consultant of this Agreement, and that, in addition to all other remedies available to OptimizeRx
at law or in equity, OptimizeRx shall be entitled to injunctive relief for the enforcement of its rights and to an accounting
of profits made during the period of such breach.

 

11.
NO RIGHTS GRANTED. Consultant understands that nothing in this Agreement shall be deemed to constitute, by implication or otherwise,
the grant by OptimizeRx to the Consultant of any license or other right under any patent, patent application or other intellectual
property right or interest belonging to OptimizeRx.

 

12.
SEVERABILITY.

 

(a)
Each of the covenants provided in this Agreement are separate and independent covenants. If any provision of this Agreement shall
be determined to be invalid or unenforceable, the remainder of this Agreement shall not be affected thereby and any such invalid
or unenforceable provision shall be reformed so as to be valid and enforceable to the fullest extent permitted by law.

 

(b)
It is not a defense to the enforcement of any provision of this Agreement that OptimizeRx has breached or failed to perform any
obligation or covenant hereunder or under any other agreement or understanding between Consultant and OptimizeRx.

 

13.
GOVERNING LAW. This Agreement shall be governed by and construed in accordance with the laws of the State of Michigan without
regard to conflict of law rules. All suits and claims shall be made only in state or federal courts located in Detroit, Michigan.

 

14.
SUPERSEDES OTHER AGREEMENTS. This Agreement contains the entire agreement of the parties with respect to subject matter hereof
and supersedes all previous agreements and understandings between the parties with respect to its subject matter.

 

15.
AMENDMENTS. This Agreement may not be changed, modified, released, discharged, abandoned or otherwise terminated in whole or in
part except by an instrument in writing, agreed to and signed by the Consultant and a duly authorized officer of OptimizeRx.

 

16.
ACKNOWLEDGEMENTS. THE CONSULTANT ACKNOWLEDGES THAT (i) THE CONSULTANT HAS READ AND FULLY UNDERSTANDS THIS AGREEMENT; (ii) THE
CONSULTANT HAS BEEN GIVEN THE OPPORTUNITY TO ASK QUESTIONS; (iii) THE CONSULTANT HAS RECEIVED A COPY OF THIS AGREEMENT, THE ORIGINAL
OF WHICH WILL BE RETAINED IN THE CONSULTANT’S PERSONNEL FILE; AND (iv) THE CONSULTANT’S OBLIGATIONS UNDER THIS AGREEMENT
SURVIVE THE TERMINATION OF THE CONSULTANT’S CONSULTING WITH OPTIMIZERX FOR ANY REASON.

 

    	 	4	 

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Agreement as of the date set forth below.

 

OptimizeRx
Corp.

 

	/s/
     Douglas Baker	 
	Douglas
                                         Baker
	 
	Chief
    Financial Officer	 
	OptimizeRx,
    Inc.	 
	 	 
	 	 
	Date	 
	 	 
	Consultant	 
	 	 
	 	 
	Signature	 
	 	 
	 	 
	Name
    Printed	 
	 	 
	 	 
	Date	 

  

    	 	5	 

     

    

 

Schedule
A

 

None
beyond what has been assigned to the company.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}]]